our method uses XFI to enable yet unseen data

The main tool of X-ray Fluorescence Imaging (XFI) allows for in-vivo tracking of medical drugs as well as labeled immune cells, an unprecedented tool for new insights into e.g. immune mediated inflammatory diseases, or for cell therapy and nanomedicine. 

In contrast to optical fluorescence and/or bioluminescence, XFI does not suffer from any imaging depth limitation. XFI exhibits a significantly larger sensitivity in terms of nanoparticle detectability compared to CT or MRI. In contrast to PET and SPECT, XFI is easier to handle as no radiochemistry is necessary and there is no limit in the time-window, since the nanoparticles emit fluorescence signals over arbitrary times. 

This opens completely new insights and due to the simultaneous assessment it saves testing numbers and time - a game changer in drug development and therapies.

 

We provide you with new data for new insights!

 

customers' demand

The effect of any administered therapeutic is mainly determined by the concentration that it reaches at the target site (1). If a newly developed drug, for instance against Alzheimer's Disease, Cancer, Coronary heart (& stroke), Crohn's Disease and Diabetes mellitus, which are among the TOP 10 causes of death with around 31 million events/year (2), does not reach the target area with sufficient concentration, its curing efficacy can be expected to be insignificant.

Hence, an imaging method that could provide a quantitative in-vivo tracking of therapeutics, is of high impact. Apart from such a next-generation pharmacokinetics, which would allow the quantitative localization of administered medical drugs, one could use the same methodology for localizing medical diagnostic agents. For instance, such agents could target immune cells for monitoring inflammations.

These unprecedented imaging capabilities for a faster & more effective market access of medical innovations is highly interesting to reduce the average costs of up to 6 billion USD of drug development, reduce the average timeline of 13 years till market launch and increase at the same moment ROI due to limited patent time of 20 years.

 

  1. J. Vrbanac, R. Slauter, in A Comprehensive Guide to Toxicology in Nonclinical Drug Development (Second Edition), 2017
  2. World Health Organization. Fact Sheet No. 310. http://www.who.int/mediacentre/factsheets/fs310/en

our solution

axiom insights’s solution is based on the advancement of current X-ray fluorescence imaging state-of-the-art by IP-protected new developments owned by axiom insights.
XFI uses nanparticles that can be excited to emit "X-ray echos" (i.e. X-ray fluoresence) and by recording these "echos" the nanoparticles are localized in-vivo. The medical drugs or diagnostic agents are bound on the nanoparticles, or cells are loaded with them. The biomarkers under study are thus localized by localizing the nanoparticles.

See our proof of concept puiblication here.

This offers several aspects which the pharma industry and other research customers will benefit from:

  • in-vivo tracking of labeled cells or nanomedicine tools
  • knowing where injected cells and/or drug carriers move is important knowledge for drug development and toxicity assessment
  • cut cost of drugs' dose-finding studies
  • save time during pre-clinical phase and above
  • get insights that tools of nuclear medicine cannot deliver
  • reduce animal testing enormously
  • new data on binding of ligends to druggable target structures
  • docking at target area or in region of interest